27% of all new drug approvals in USA for cancer therapies

6 September 2019

Cancer drugs currently account for 27% of all new drug approvals in the USA since 2010, a dramatic increase from the 4% share of the 1980s, according to a newly-completed analysis.

From 1980 through 2018, the Food and Drug Administration approved a total of 126 cancer drugs to treat solid and hematologic tumors, the study from the Tufts Center for the Study of Drug Development shows.

"New approaches to development helped to drive the surge in new oncology products, including improvements in clinical trial design, novel drug formats, and a focus on new and validated targets,” said Joseph DiMasi, research associate professor and director of economic analysis and at Tufts CSDD, who conducted the analysis. “Those efforts appear to have paid off, as cancer patients today have many more effective treatment options," he added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK